Promoted Content
Promoted Content

Find Clinical Drug Pipeline Developments & Deals by BeiGene

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Therapeutic Area filter
    Study Phase filter
      Country filter
        News Type filter
          Company filter
            refresh

            Companies By Therapeutic Area Full Screen

            Development Status Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): DKN-01,Tislelizumab,Oxaliplatin

            Therapeutic Area: Oncology Product Name: DKN-01

            Highest Development Status: Phase II Product Type: Large molecule

            Recipient: Leap Therapeutics

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 24, 2020

            Details:

            DKN-01 is a humanized monoclonal antibody that binds to and blocks the activity of DKK1 protein, a modulator of Wnt/Beta-catenin signaling.DKN-01 is currently being evaluated in clinical trials for gastroesophageal, gynecologic, hepatobiliary, and prostate cancers.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): DKN-01,Tislelizumab,Oxaliplatin

            Therapeutic Area: Oncology Product Name: DKN-01

            Highest Development Status: Phase II Product Type: Large molecule

            Recipient: Leap Therapeutics

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 21, 2020

            Details:

            First patient has been dosed in the DisTinGuish study evaluating Leap's investigational anti-Dickkopf-1 antibody, DKN-01, in combination with tislelizumab, BeiGene's anti-PD-1 antibody, with or without chemotherapy, in patients with gastric or gastroesophageal junction cancer.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Tislelizumab,Carboplatin,Paclitaxel

            Therapeutic Area: Oncology Product Name: BGB-A317

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 17, 2020

            Details:

            Tislelizumab in combination with pemetrexed and platinum chemotherapy has demonstrated encouraging results among advanced NSCLC patients with non-squamous histology, including a median progression-free survival of 9.7 months and an overall response rate of 57.4 percent.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Zanubrutinib

            Therapeutic Area: Oncology Product Name: Brukinsa

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 09, 2020

            Details:

            The Health Canada has accepted for review and granted priority review status to BeiGene's marketing application seeking approval of BTK inhibitor Brukinsa (zanubrutinib) for the treatment of Waldenström’s macroglobulinemia (WM).

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): DXP-593

            Therapeutic Area: Infections and Infectious Diseases Product Name: DXP-593

            Highest Development Status: Preclinical Product Type: Large molecule

            Recipient: Singlomics

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement August 27, 2020

            Details:

            Under the terms of the agreement, Singlomics has granted BeiGene exclusive rights in ex-China territory to develop, manufacture, and commercialize its preclinical assets DXP-593 and DXP-604, as well as for a series of antibody sequences that could target the COVID-19 virus.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Bevacizumab

            Therapeutic Area: Oncology Product Name: BAT1706

            Highest Development Status: Phase III Product Type: Large molecule

            Recipient: Bio-Thera Solutions Ltd

            Deal Size: $165.0 million Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement August 24, 2020

            Details:

            Under the terms of the agreement, Bio-Thera has agreed to grant BeiGene the right to develop, manufacture, and commercialize BAT1706 in China, including Hong Kong, Macau, and Taiwan.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Pamiparib,Temozolomide

            Therapeutic Area: Oncology Product Name: BGB-290

            Highest Development Status: Phase I/ Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 05, 2020

            Details:

            Clinical and nonclinical data on its anti-PD-1 antibody tislelizumab and its investigational PARP inhibitor pamiparib will be presented in two mini oral presentations and five posters at the 2020 European Society for Medical Oncology (ESMO) Virtual Congress.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Pamiparib

            Therapeutic Area: Oncology Product Name: BGB-290

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 27, 2020

            Details:

            The NDA of pamiparib as a potential treatment for patients with advanced ovarian, fallopian tube, or primary peritoneal cancer was accepted in July 2020. It is supported by clinical results from the pivotal Phase 2 portion of the Phase 1/2 trial.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ABI-H0731

            Therapeutic Area: Infections and Infectious Diseases Product Name: ABI-H0731

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: BeiGene

            Deal Size: $540.0 million Upfront Cash: $40.0 million

            Deal Type: Licensing Agreement July 20, 2020

            Details:

            BeiGene acquires exclusive development and commercialization rights to ABI-H0731, ABIH2158, and ABI-H3733 in China

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Denosumab

            Therapeutic Area: Oncology Product Name: Xgeva

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: Amgen Inc

            Deal Size: $421.0 million Upfront Cash: Undisclosed

            Deal Type: Investment July 12, 2020

            Details:

            This additional investment reflects Amgen's confidence in the progress the companies are making in their ongoing oncology collaboration in China, the world's second largest pharmaceutical market.

            PharmaCompass